Table 3 Antibiotics with NDA/MAA submitted or in phase-III clinical trials (structures in Figs. 3 and 4)
From: Antibiotics in the clinical pipeline as of December 2022
Name (synonym)a | Compound class (lead source) | Mode of actiona | Administration; indication (developer) |
|---|---|---|---|
NDA/MAA | |||
solithromycin (6) (T-4288) | erythromycin (NP) | protein synthesis inhibition | IV/po; respiratory tract infection (FUJIFILM Toyama) |
Phase-III | |||
sulopenem (6) (IV) sulopenem etzadroxil (7) (prodrug) + probenecid (8) | penem (NP) | PBP (cell wall) | po; uUTI, cUTI and cIAI (Iterum Therapeutics) |
nafithromycin (9) (WCK 4873) | macrolide (NP) | protein synthesis | po; CABP (Wockhardt) |
gepotidacin (10) (GSK-2140944) | triazaacenaphthylene (S) | DNA gyrase (GyrA) — different to quinolones | po; UTI and gonorrhea (GSK) |
zoliflodacin (11) (ETX0914) | spiropyrimidinetrione (S) | DNA gyrase (GyrB) | po; gonorrhea (Innoviva / GARDP) |
Phase-II/III | |||
benapenem (12) | carbapenem (NP) | PBP (cell wall) | IV; UTI (Sihuan Pharmaceuticals) |
epetraborole (13) (BRII-658) | oxaborole (S) | leucyl-tRNA synthetase (LeuRS) – protein synthesis | po; NTM with a focus on M. avium (AN2 Therapeutics / Brii Biosciences) |
